NEJM: 15-year Osteoporosis Screening Gap OK for Many
Women with normal bone density are unlikely to develop osteoporosis within 15 years and can forego the duel-energy X-ray absorptiometry (DXA) radiology exams to detect it for at least that long.
Women with normal bone density are unlikely to develop osteoporosis within 15 years and can forego the duel-energy X-ray absorptiometry (DXA) radiology exams to detect it for at least that long, researchers reported online January 19 in the New England Journal of Medicine.
A team led by Margaret Gourlay, MD, MPH, of the University of North Carolina at Chapel Hill, tracked 4,957 women ages 67 and older for 15 years. The women had normal bone mineral density (BMD) or osteopenia (low BMD) and no history of hip or vertebra fracture, or treatment for osteoporosis. The aim was to provide a foundation for decisions about the interval between BMD tests.
The team defined an ideal BMD testing interval as the estimated time for 10 percent of women to make the transition to osteoporosis, but not yet break a hip or crack vertebrae.
Over the course of the study, 0.8 percent of women with normal BMD developed osteoporosis; among those with those with mild, moderate, and advanced osteopenia, 4.6 percent, 20.9 percent, and 62.3 percent developed it, respectively.
For women with normal BMD, the team established estimated testing intervals 16.8 years for women with normal BMD and 17.3 years for women with mild osteopenia. Women with moderate and advanced osteopenia would need more frequent testing, the team says - at 4.7 years and 1.1 years.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
